CAS 151038-96-9
:DOXO-EMCH
Description:
DOXO-EMCH, with the CAS number 151038-96-9, is a chemical compound that serves as a prodrug of doxorubicin, a well-known chemotherapeutic agent. This compound is characterized by its ability to selectively release doxorubicin in targeted tissues, enhancing the drug's therapeutic efficacy while minimizing systemic toxicity. DOXO-EMCH is typically designed to improve the pharmacokinetics and biodistribution of doxorubicin, allowing for more effective cancer treatment. The structure of DOXO-EMCH includes a linker that facilitates the release of doxorubicin upon enzymatic cleavage, which is often mediated by specific enzymes present in the tumor microenvironment. This targeted approach aims to increase the concentration of the active drug at the tumor site, thereby improving the overall treatment outcome. Additionally, the compound's solubility, stability, and metabolic profile are crucial for its performance in clinical settings. As research continues, DOXO-EMCH represents a promising avenue in the development of more effective cancer therapies with reduced side effects.
Formula:C37H42N4O13
InChI:InChI=1/C37H42N4O13/c1-17-32(46)20(38)13-27(53-17)54-22-15-37(51,23(16-42)39-40-24(43)9-4-3-5-12-41-25(44)10-11-26(41)45)14-19-29(22)36(50)31-30(34(19)48)33(47)18-7-6-8-21(52-2)28(18)35(31)49/h6-8,10-11,17,20,22,27,32,42,46,48,50-51H,3-5,9,12-16,38H2,1-2H3,(H,40,43)/b39-23+
InChI key:InChIKey=OBMJQRLIQQTJLR-FRTGXRTISA-N
SMILES:OC=1C2=C([C@@H](O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C[C@@](C(=NNC(CCCCCN4C(=O)C=CC4=O)=O)CO)(O)C2)C(O)=C5C1C(=O)C=6C(C5=O)=C(OC)C=CC6
Synonyms:- 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (1-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2S-cis)-
- 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
- 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
- 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[4-[(3-amino-2,3,6-trideoxy-α-<span class="text-smallcaps">L</span>-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide, (2S-cis)-
- 2,5-Dihydro-2,5-dioxo-1H-pyrrole-1-hexanoic acid (1-(4-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-hydroxyethylidene)hydrazide, (2S-cis)-
- Aldoxorubicin
- Doxo-Emch
- Doxorubicin-EMCH
- MC-Doxhzn
- N'-[(1E)-1-{4-[(3-amino-2,3,6-trideoxyhexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanehydrazide
- 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, 2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
- 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
- 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, [1-[4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide, (2S-cis)-
- Doxorubicin(6-maleimidocaproyl)hydrazone
- INNO-206 (Aldoxorubicin)
- 1H-Pyrrole-1-hexanoicacid, 2,5-dihydro-2,5-dioxo-, [1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide
- Doxorubicin-hydrazone-caproyl-maleimide
- N'-[(1E)-1-{4-[(3-Amino-2,3,6-trideoxyhexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl}-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexane hydrazide
- INNO-206
- DOXO-EMCH; DOXORUBICIN-EMCH; INNO206;INNO 206;ALDOXORUBICIN
- See more synonyms
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.
Doxorubicin-hydrazone-caproyl-maleimide
CAS:Controlled ProductFormula:C37H42N4O13Color and Shape:NeatMolecular weight:750.75Doxorubicin-hydrazone-caproyl-maleimide
CAS:<p>a 6-maleimidocaproyl hydrazone derivative of Doxorubicin which is an albumin binding prodrug. It is acid sensitive and selectively binds to the cysteine-34 position of circulating albumin.</p>Formula:C37H42N4O13Purity:Min. 95%Color and Shape:PowderMolecular weight:750.75 g/molMC-DOXHZN
CAS:Mc-doxhzn is a protein-binding prodrug of DOXUbicin (DNA topoisomerase II inhibitor) with acid sensitivity.Formula:C37H42N4O13Purity:98%Color and Shape:SolidMolecular weight:750.75



